Invivyd (IVVD) Cash from Investing Activities (2021 - 2025)
Invivyd (IVVD) posted Cash from Investing Activities of -$11000.0 for Q2 2025, up 92.36% on a QoQ basis from -$144000.0 in Q1 2025.
Invivyd (IVVD) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Invivyd's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$11000.0 for Q2 2025.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$11000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$155000.0 (down 10.71% YoY) and the FY2025 annual result came in at -$155000.0, down 10.71% from the prior year.
- Cash from Investing Activities was -$11000.0 for Q2 2025 at Invivyd, up from -$144000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $137.9 million in Q4 2021 and bottomed at -$188.6 million in Q3 2021.
- A 5-year average of -$65933.3 and a median of -$5000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 200.65% — and 2023, when it soared 191835.29%.
- Invivyd's Cash from Investing Activities stood at $137.9 million in 2021, then plunged by 200.65% to -$138.8 million in 2022, then jumped by 156.13% to $77.9 million in 2023, then slumped by 99.99% to $5000.0 in 2024, then tumbled by 320.0% to -$11000.0 in 2025.
- Business Quant data shows IVVD's Cash from Investing Activities at -$11000.0 in Q2 2025, -$144000.0 in Q1 2025, and $5000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Invivyd | 104.89 Mn | -121.79 Mn | 16.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -144,000.00 |
| Mar 31, 2025 | -144,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Dec 31, 2023 | 77.92 Mn |
| Dec 31, 2023 | 77.92 Mn |
| Sep 30, 2023 | 95.14 Mn |
| Sep 30, 2023 | 95.14 Mn |
| Jun 30, 2023 | 32.60 Mn |
| Jun 30, 2023 | 32.60 Mn |
| Mar 31, 2023 | 75.04 Mn |
| Mar 31, 2023 | 75.04 Mn |
| Dec 31, 2022 | -138.81 Mn |
| Dec 31, 2022 | -138.81 Mn |